Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

By Meagan Parrish • Sept. 27, 2022

Why precision medicine could be the next frontier in treating autism

Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

By Kelly Bilodeau • Sept. 27, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Methadone at home? Emerging tech provides new tool in the fight against opioid addiction

Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.

By Alexandra Pecci • Sept. 15, 2022

Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

By Taren Grom • Sept. 14, 2022

Feds could soon bring COVID-style fight to superbug threat

COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

By Karissa Waddick • Sept. 13, 2022

Clinical registry data, a valuable source of real-world data

Real-world data (RWD) from clinical drug registries can and should be used throughout the drug development lifecycle. At all stages, registries ensure that assumptions about the current standard of care are accurate and evidence-based.

By CorEvitas • Sept. 6, 2022

Pharma’s renewed sickle cell investment lifts a once-shirked disease

Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

By Kelly Bilodeau • Sept. 1, 2022

Woman of the Week: Thread’s Kim Boericke

Fresh off an eight-year tour of duty at ICON, the CRO industry veteran is stepping into a new role and a new title as chief delivery officer at Thread.

By Taren Grom • Aug. 31, 2022

Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

By Karissa Waddick • Aug. 31, 2022

Parexel joins pharmacy giants in quest to boost community health clinical trials

The Community Alliance Network is the latest industry initiative looking to the pharmacy counter to help improve trial recruitment diversity.

By Taren Grom and Karissa Waddick • Aug. 30, 2022

Leading the industry’s next potential game-changer in drug discovery

Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.

By Alexandra Pecci • Aug. 29, 2022

The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact

A collaboration between Stanford University researchers and Komodo Health aims to advance knowledge of lingering COVID symptoms, health disparities and intervention strategies.

By Michael Gibney • Aug. 29, 2022

With market success at stake, can tech help solve the diversity problem in clinical trials?

Diversity in clinical trials isn’t only important for the health of the overall patient population — it can save millions in lost profits.

By Kelly Bilodeau • Aug. 24, 2022

Woman of the Week: Glympse Bio’s Dr. Tram Tran

How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.

By Taren Grom • Aug. 24, 2022

Overcoming mental health’s drug development challenges with AI

PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant depression.

By Kelly Bilodeau • Aug. 23, 2022

First 90 Days: Agios Pharmaceuticals’ Brian Goff

The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.

By Alexandra Pecci • Aug. 22, 2022

Woman of the Week: Takeda Oncology’s Teresa Bitetti

Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.

By Taren Grom • Aug. 17, 2022

Inventing the COVID vax pill: a matter of convenience and durability

Recent data from Vaxart’s phase 1 trial of its COVID-19 inoculation pill shows potential.

By Kelly Bilodeau • Aug. 17, 2022

The CEO in the ophthalmologist’s coat

In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.

By Alexandra Pecci • Aug. 16, 2022

Right under our noses: Could COVID-19 vaccines be better as nasal spray?

Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

By Kelly Bilodeau • Aug. 16, 2022

Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

By Alexandra Pecci • Aug. 9, 2022

How real world evidence is impacting rare disease drug development

ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

By Kim Ribbink • Aug. 9, 2022

The ‘alarming’ spread of Monkeypox — by the numbers

With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

By Meagan Parrish • Aug. 8, 2022

Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

How these latest executive personnel changes are impacting the industry. 

By Karissa Waddick • Aug. 3, 2022

‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients

EverythingALS aims to speed drug development through improved diagnostics.

By Kelly Bilodeau • Aug. 2, 2022